Combination therapy in multiple sclerosis

Current Neurology and Neuroscience Reports

Volumn 5, Issue 3, 2005, Pages 245-248

  Tullman, Mark J ^a   Lublin, Fred D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA1A INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; CORTICOSTEROID; GADOLINIUM; GLATIRAMER; INTERFERON BETA SERINE; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; PLACEBO;

ANTIINFLAMMATORY ACTIVITY; CELL PROLIFERATION; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; IMMUNOMODULATION; INHIBITION KINETICS; MEDICAL DECISION MAKING; META ANALYSIS; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RELAPSE; REVIEW; SYSTEMATIC REVIEW; TH2 CELL; TREATMENT OUTCOME;

EID: 21044453044     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-005-0053-9     Document Type: Review

References (33)

1. Jacobs LD, Cookfair DL, Rudick RA, et al.: Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996, 39:285-294.
2. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993, 43:655-661.
3. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998, 352:1498-1504.
4. Johnson KP, Brooks BR, Cohen JA, et al.: Copolymer 1 reduces relapse rate and improves disability in relapsing- remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995, 45:1268-1276.
5. Hartung HP, Gonsette R, Konig N, et al.: Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002, 360:2018-2025.
6. Lublin FD, Baier M, Cutter G: Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003, 61:1528-1532.
7. Gomberg-Maitland M, Frison L, Halperin JL: Active-control clinical trials to establish equivalence or noninferiority: methodological and statistical concepts linked to quality. Am Heart J 2003, 146:398-403.
8. Edwards JC, Szczepanski L, Szechinski J, et al.: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572-2581.
9. Palella FJ Jr, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
10. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group. Lancet 1991, 337:441-446.
11. Confavreux C, Saddier P, Grimaud J, et al.: Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology 1996, 46:1607-1612.
12. Yudkin PL, Ellison GW, Ghezzi A, et al.: Overview of azathioprine treatment in multiple sclerosis. Lancet 1991, 338:1051-1055.
13. Goodkin DE, Rudick RA, VanderBrug M, et al.: Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995, 37:30-40.
14. Vermersch P, Waucquier N, Bourteel H, et al.: Treatment of multiple sclerosis with a combination of interferon beta-1a (Avonex) and mycophenolate mofetil (Cellcept): results of a phase II clinical trial. Neurology 2004, 62(Suppl 5):A259.
15. Calabresi PA, Bash CN, Costello K, et al.: Optimization of the safety and efficacy of interferon beta-1b and azathioprine combination therapy in multiple sclerosis. Neurology 2004, 62(Suppl 5):A491.
16. Trapp BD, Peterson J, Ransohoff RM, et al.: Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998, 338:278-285.
17. Yong VW: Immunopathogenesis of multiple sclerosis. Multiple Sclerosis: Continuum: Lifelong Learning in Neurology 2004, 10:11-27.
18. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1999, 53:457-465.
19. Natalizumab Package Insert. Biogen Idec; November, 2004.
20. FDA Drug Advisory: Natalizumab. http://www.fda.gov/cder/drug/advisory/natalizumab.htm. Accessed March 2, 2005.
21. Noseworthy JH, O'Brien P, Erickson BJ, et al.: The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis. Neurology 1998, 51:1342-1352.
22. Noseworthy JH, Wolinsky JS, Lublin FD, et al.: Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators. Neurology 2000, 54:1726-1733.
23. Rice GP, Filippi M, Comi G: Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 2000, 54:1145-1155.
24. Cohen J, Antel J, Calabresi P, et al.: Rational and design of the Avonex combination trial. Mult Scler 2003, 9(Suppl 1):S139.
25. Yong VW: Differential mechanisms of action of interferon-beta and glatiramer aetate in MS. Neurology 2002, 59:802-808.
26. Brod SA, Lindsey JW, Wolinsky JS: Combination therapy with glatiramer acetate (copolymer-1) and a type I interferon (IFN-alpha) does not improve experimental autoimmune encephalomyelitis. Ann Neurol 2000, 47:127-131.
27. Comi G, Filippi M, Wolinsky JS: European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiram Milo R, Panitch H. Additive effects of copolymer-1 and interferon beta-1b on the immune response to myelin basic protein. J Neuroimmunol 1995, 61:185-193.
28. Lublin F, Cutter C, Elfont R, et al.: A trial to assess the safety of combining interferon beta-1a and glatiramer acetate in patients with relapsing MS. Neurology 2001, 56(Suppl 3):A148.
29. Lublin F, Baier M, Cutter G, et al.: Results of the extension of a trial to assess the longer term safety of combining interferon beta-1a and glatiramer acetate. Neurology 2002, 58(Suppl 3):A85.
30. Comi G, Filippi M, Wolinsky JS: European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging - measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001, 49:290-297.
31. Dhib-Jalbut S, Chen M, Henschel K, et al.: Effect of combined IFN beta-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis. Mult Scler 2002, 8:485-491.
32. Filippi M, Rovaris M, Rocca MA, et al.: Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes." Neurology 2001, 57:731-733.
33. Ziemssen T, Kumpfel T, Klinkert WE, et al.: Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain 2002, 125(Pt 11):2381-2391.